A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer
OSI-7904L is a liposomal formulation of a potent thymidylate synthase (TS) inhibitor. This phase I study evaluated the safety, tolerability and pharmacokinetics (PK) of OSI-7904L administered in combination with oxaliplatin every 21 days in patients with advanced colorectal carcinoma.
A 3+3 study design was utilized at predefined dose levels. Polymorphisms in the TS enhancer region and XPD enzyme were investigated as potential predictors of efficacy and toxicity.
Fourteen patients received 76 cycles of treatment. At the highest dose level (OSI-7904L 9 mg/m2, oxaliplatin 130 mg/m2) investigated, one of nine patients experienced dose-limiting toxicity of grade 3 oral mucositis with cycle 1 and five further patients required dose reductions. The toxicity profile of stomatitis, diarrhea, nausea, fatigue, sensory neuropathy and skin rash was consistent with that expected for a TS inhibitor/oxaliplatin combination regimen. PK analysis showed high interpatient variability with no detectable interaction between OSI-7904L and oxaliplatin. Partial radiological responses were documented in two patients.
The recommended regimen for further investigation is OSI-7904L 9 mg/m2 and oxaliplatin 130 mg/m2.
KeywordsPhase I OSI-7904L Oxaliplatin Thymidylate synthase Colorectal carcinoma
The authors would like to thank Dr. D. W. Drolet for his assistance in the pharmacokinetic analyses.
The study sponsor was OSI Pharmaceuticals Inc. Study design, data collection, interpretation and decision to submit the manuscript for publication were undertaken by the EORTC in conjunction with the authors.
Conflict of interest statement
J. Chick is an employee of OSI Pharmaceutical Inc. and hold share options in this company. None of the other authors have any conflict of interest.
- 6.De Gramont A, Bosset JF, Milan C et al (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808–815PubMedGoogle Scholar
- 9.Desjardins J, Emerson DL, Colagiovanni DB, Abbott E, Brown EN, Drolet DW (2004) Pharmacokinetics, safety and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice. J Pharmacol Exp Ther 309:894–902PubMedCrossRefGoogle Scholar
- 11.Winski S, Nilsson C, Brown E et al (2002) In vivo antitumor efficacy of liposomal OSI-7904L in human tumor xenografts. NCI-EORTC-AACR Molecular targets and cancer therapeutics meeting, 2002 Abstract 119Google Scholar
- 12.Pendyala L, Leichman CG, Clark K et al (2001) Oxaliplatin influences the intra-tumoral expression of γ-glutamylcysteine synthetase and thymidylate synthase genes in patients with esophagus cancer. Proc Am Soc Clin Oncol 20, 351aGoogle Scholar
- 20.Cancer Therapy Evaluation Programme (2003) Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS. December 12 2003. (http://www.ctep.cancer.gov/reporting/ctc_v3.0)
- 26.Ford HER, Mitchell F, Cunningham D et al (2002) Patterns of elevation of plasma 2′-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res 8:103–109PubMedGoogle Scholar